Capital One National Association’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capital One National Association’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$875K	Sell	9,294 -838	-8%	-$73.4K	0.06%	238
2018 Q1	$821K	Sell	10,132 -114	-1%	-$9.78K	0.06%	257
2017 Q4	$914K	Sell	10,246 -268	-3%	-$23.3K	0.06%	242
2017 Q3	$979K	Sell	10,514 -65	-0.6%	-$5.74K	0.07%	229
2017 Q2	$961K	Sell	10,579 -49	-0.5%	-$4.46K	0.07%	232
2017 Q1	$933K	Buy	10,628 +874	+9%	+$77.8K	0.07%	231
2016 Q4	$808K	Buy	9,754 +3,212	+49%	+$276K	0.06%	248
2016 Q3	$605K	Buy	+6,542	New	+$616K	0.05%	287

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital One National Association's BMRN Position: Q2 2018 in Review

Capital One National Association reduced its BioMarin Pharmaceuticals (BMRN) stake by 8.3% in Q2 2018, selling an estimated $73.4K and leaving 9,294 shares worth $875K. The position accounts for 0.06% of the portfolio, ranked #238.

Capital One National Association first reported a position in BMRN in Q3 2016 and has held it in 8 quarters since. The position peaked at $979K in Q3 2017. 448 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

Capital One National Association held 9,294 shares of BioMarin Pharmaceuticals worth $875K as of Q2 2018.
Capital One National Association sold 838 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $73.4K.
BioMarin Pharmaceuticals made up 0.06% of Capital One National Association's portfolio in Q2 2018, its #238 holding.
Capital One National Association first reported a position in BioMarin Pharmaceuticals in Q3 2016 and has held it in 8 quarters since.
Capital One National Association's BioMarin Pharmaceuticals position peaked at $979K in Q3 2017.
448 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on Capital One National Association's 13F filing for Q2 2018, filed 16 Jul 2018.